Hubert Czerniak TV #25 Tajemniczy aminokwas niszczący zdrowie / Poznaj przyczynę chorób

Czerniak describes Homocysteina 100W as the only supplement he knows of that combines all necessary active cofactors at therapeutic doses. He values that it uses the maximum allowed 50 mg of riboflavin (any higher would be a pharmaceutical dose) and active B6 (pyridoxal-5-phosphate). The inclusion of niacin (as nicotinic acid) is intentional: while he personally likes the immediate flush – which signals vasodilation – he acknowledges that many patients find it distressing, so the manufacturer opted for a gradual-release form to avoid acute flushing, making it tolerable for adults while still supporting HDL, lowering LDL indirectly, and addressing homocysteine-induced damage. He notes that this formulation helps type 2 diabetics reduce complication risk because it addresses the underlying endothelial dysfunction. The supplement is presented as a complete package that doesn’t just block cholesterol synthesis (the ‘symptom’ approach) but corrects the methylation defect, thereby restoring the body’s own LDL regulation. The vegetable capsule makes it suitable for vegans.

Czerniak provides a specific list that echoes natural medicine advice: botwinka, sałata, jarmuż, ciemna sałata, szparagi, awokado, kiełki fasoli, brukselka, brokuły, and całe pomarańcze – with emphasis on the white inner fibres (albedo) under the peel. He doesn’t mean the peel itself but the white strands, which many discard. This tidbit is practical and rarely mentioned; it directly targets dietary folate intake without the pitfalls of synthetic folic acid. In the context of the methylation discussion, he’s teaching patients to obtain natural 5-MTHF precursors, trusting that whole-food matrix provides the necessary cofactors like B2 and B6 that also come partly from these foods. He implicitly discourages relying solely on fortified grains with folic acid.

Czerniak walks through the enzymes: MTHFR methylates homocysteine; CBS and CBN handle the transsulfuration. He explains that a single nucleotide polymorphism in MTHFR at position 677 leads to a 65% drop in enzyme production, directly limiting remethylation. If a patient also carries CBS or CBN mutations, the alternative breakdown route is hampered, resulting in severe homocysteine elevation. In his practice, he integrates this with MCV (mean corpuscular volume) – high MCV signals B12/folate deficiency. By testing genes, he argues you can stop guessing and provide the exact active vitamins (like the ones in Homocysteina 100W) at the necessary doses, avoiding under-treatment or masking syndromes.

Czerniak details that the supplement Homocysteina 100W contains 5-methyltetrahydrofolate (which he refers to as ‘łatwe folii’ – easy folate – and ‘skład reform’), the only folate form that has clinical studies, is water-soluble, and crosses the blood-brain and placental barriers. He explicitly warns that folic acid masks the 13 symptoms of B12 deficiency – confusion, hair loss, tachycardia, eczema, sore tongue, loss of appetite, weight loss, abdominal pain, growth retardation, paresthesias, depression, pale skin, fatigue, muscle cramps, anaemia – while methylfolate does not. He uses this to argue that all homocysteine-lowering formulas must use active folate to avoid neurological tragedy, especially in patients with suspected or unknown B12 malabsorption.

Czerniak explains the two metabolic fates of homocysteine: remethylation to methionine (requiring B12, zinc, copper, methylfolate) and transsulfuration to cystathionine (requiring B6). When either pathway fails due to nutrient lack or genetic polymorphism (MTHFR C677T causing 65% enzyme loss, CBS/CBN impairing B6/B12 usage), homocysteine accumulates. This accumulation then wreaks havoc across systems: it stiffens arteries via collagen damage, ignites oxidative cascades that modify LDL into more atherogenic forms, prompts platelet aggregation, and in the brain stimulates microglia with neurotoxic consequences. He thus positions the methylation cycle as the master switch for degenerative disease, with homocysteine as its measurable readout and therapeutic target.